Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michelle Quinlan

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Frontiers in Clinical Diabetes and Healthcare|September 27, 2023
Investigating the value of glucodensity analysis of continuous glucose monitoring data in type 1 diabetes: an exploratory analysisElvis Han Cui, Allison B Goldfine, Michelle Quinlan, et al.
British Journal of Clinical Pharmacology|June 10, 2016
Effect of esomeprazole, a proton pump inhibitor on the pharmacokinetics of sonidegib in healthy volunteersJocelyn Zhou, Michelle Quinlan, Kelli Glenn, et al.
Clinical Pharmacokinetics|February 17, 2023
Justifying Ribociclib Dose in Patients with Advanced Breast Cancer with Renal Impairment Based on PK, Safety, and Efficacy Data: An Innovative Approach Integrating Data from a Dedicated Renal Impairment Study and Oncology Clinical TrialsYan Ji, Vitaly Yartsev, Michelle Quinlan, et al.
Clinical Pharmacokinetics|January 20, 2024
Use of Pharmacokinetic and Pharmacodynamic Data to Develop the CDK4/6 Inhibitor Ribociclib for Patients with Advanced Breast CancerYan Ji, Hilmar Schiller, Shu Yang, et al.
Clinical Pharmacology in Drug Development|October 5, 2021
Pharmacokinetics of Asciminib When Taken With Imatinib or With FoodMatthias Hoch, Julia Zack, Michelle Quinlan, et al.
Clinical and Translational Science|May 26, 2022
Pharmacokinetics of asciminib in the presence of CYP3A or P-gp inhibitors, CYP3A inducers, and acid-reducing agentsMatthias Hoch, Felix Huth, Masahiko Sato, et al.
Journal of Clinical Pharmacology|June 11, 2021
Pharmacokinetics of Asciminib in Individuals With Hepatic or Renal ImpairmentMatthias Hoch, Masahiko Sato, Julia Zack, et al.
British Journal of Clinical Pharmacology|May 28, 2021
Pharmacokinetics of capmatinib in participants with hepatic impairment: A phase 1, open-label, single-dose, parallel-group studyXinhui Chen, Xiaoming Cui, Nathalie Pognan, et al.
Cancer Chemotherapy and Pharmacology|September 7, 2014
The effect of formulation and food consumption on the bioavailability of dovitinib (TKI258) in patients with advanced solid tumorsSunil Sharma, Carolyn D Britten, Joanne Mortimer, et al.
British Journal of Clinical Pharmacology|December 10, 2020
Effect of capmatinib on the pharmacokinetics of digoxin and rosuvastatin administered as a 2-drug cocktail in patients with MET-dysregulated advanced solid tumours: A phase I, multicentre, open-label, single-sequence drug-drug interaction studyEnrique Grande, Monica Giovannini, Eddie Marriere, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Frontiers in Clinical Diabetes and Healthcare|September 27, 2023
Investigating the value of glucodensity analysis of continuous glucose monitoring data in type 1 diabetes: an exploratory analysisElvis Han Cui, Allison B Goldfine, Michelle Quinlan, et al.
British Journal of Clinical Pharmacology|June 10, 2016
Effect of esomeprazole, a proton pump inhibitor on the pharmacokinetics of sonidegib in healthy volunteersJocelyn Zhou, Michelle Quinlan, Kelli Glenn, et al.
Clinical Pharmacokinetics|February 17, 2023
Justifying Ribociclib Dose in Patients with Advanced Breast Cancer with Renal Impairment Based on PK, Safety, and Efficacy Data: An Innovative Approach Integrating Data from a Dedicated Renal Impairment Study and Oncology Clinical TrialsYan Ji, Vitaly Yartsev, Michelle Quinlan, et al.
Clinical Pharmacokinetics|January 20, 2024
Use of Pharmacokinetic and Pharmacodynamic Data to Develop the CDK4/6 Inhibitor Ribociclib for Patients with Advanced Breast CancerYan Ji, Hilmar Schiller, Shu Yang, et al.
Clinical Pharmacology in Drug Development|October 5, 2021
Pharmacokinetics of Asciminib When Taken With Imatinib or With FoodMatthias Hoch, Julia Zack, Michelle Quinlan, et al.
Clinical and Translational Science|May 26, 2022
Pharmacokinetics of asciminib in the presence of CYP3A or P-gp inhibitors, CYP3A inducers, and acid-reducing agentsMatthias Hoch, Felix Huth, Masahiko Sato, et al.
Journal of Clinical Pharmacology|June 11, 2021
Pharmacokinetics of Asciminib in Individuals With Hepatic or Renal ImpairmentMatthias Hoch, Masahiko Sato, Julia Zack, et al.
British Journal of Clinical Pharmacology|May 28, 2021
Pharmacokinetics of capmatinib in participants with hepatic impairment: A phase 1, open-label, single-dose, parallel-group studyXinhui Chen, Xiaoming Cui, Nathalie Pognan, et al.
Cancer Chemotherapy and Pharmacology|September 7, 2014
The effect of formulation and food consumption on the bioavailability of dovitinib (TKI258) in patients with advanced solid tumorsSunil Sharma, Carolyn D Britten, Joanne Mortimer, et al.
British Journal of Clinical Pharmacology|December 10, 2020
Effect of capmatinib on the pharmacokinetics of digoxin and rosuvastatin administered as a 2-drug cocktail in patients with MET-dysregulated advanced solid tumours: A phase I, multicentre, open-label, single-sequence drug-drug interaction studyEnrique Grande, Monica Giovannini, Eddie Marriere, et al.
Pageof 4